Fusion Antibodies develop high expression level stable cell line for ISCA Diagnostics
FUSION ANTIBODIES DEVELOP HIGH EXPRESSION LEVEL STABLE CELL LINE FOR ISCA DIAGNOSTICS
Fusion Antibodies Develop High Expression Level Stable Cell Line for ISCA Diagnostics
Fusion Antibodies and ISCA diagnostics are happy to announce another successful project – development of stable cell line expressing a humanized version of ISCA Diagnostic’s Aspergillus-specific monoclonal antibody JF5. The cell line development project has taken place over the past 10 months and today marks its successful completion and transfer of materials to ISCA Diagnostics for commencement of work package 2 in the MATHIAS programme.
Fusion Antibodies first humanized the parental antibody before development of the cell line. Fusion Antibodies have achieved a record PCD (picograms per cell per day) of 33.5 in non-fed shake flask cultures, which will be capable of producing multiple grams per litre in a bioreactor system.
It is another successful result of cooperation with ISCA Diagnostic’s Aspergillus-specific monoclonal antibody JF5.
To find out more, see the newest press releaseTo find out more, see the newest press release